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Prolonged lifespan and high incidence of neoplasms in NZB/
NZW mice treated with hydrocortisone sodium succinate. This
study investigated the effects of prolonged corticosteiiod therapy
on the course of spontaneous autoimmune disease and oncogene-
sis in NZB/NZW mice, an animal model of systemic lupus erythe-
matosus. Twenty young female NZB/NZW mice were treated until
death with low-dose hydrocortisone sodium succinate (3.3 mg/kg/
day), and 21 mice received high-dose hydrocortisone (10 mg/kg/
day). Fifteen control mice were injected with saline. Long-term
therapy with either dose of hydrocortisone effectively prevented
renal disease and prolonged lifespans in NZB/NZW mice. Fifty-six
percent of low-dose treated animals developed neoplasms, and
38% of mice in this treatment group died with renal disease.
Neoplasms caused death in 76% of mice receiving high-dose treat-
ment. Long-term hydrocortisone therapy was associated with a
predominance of sarcomas, which appeared in aged mice after a
long period of treatment. In earlier studies conducted in this
laboratory, cyclophosphamide treatment prolonged life in NZB/
NZW mice. Ninety-seven percent of cyclophosphamide-treated
mice developed neoplasms; most tumors were lymphomas or
carcinomas, It was concluded that neoplasms occur commonly in
old NZB/NZW mice with lives prolonged by immunosuppressive
or antiinflammatory drugs. Nevertheless, the specific therapeutic
agent used in each study influenced the types of neoplasms appear-
ing in treated mice.
Allongement de Ia durée de vie et grande frequence des néopla-
sies chez les souris NZB/NZW traitées par I'hydrocortisone (succi-
nate sodique). Ce travail étudie les effets de Ia corticothérapie
prolongée sur l'évolution de l'affection autoimmune spontanée et
de Ia cancérisation chez les souris NZB/NZW, un modèle animal
de lupus érythémateux. Vingt jeunes souris femelles NZB/NZW
ont été traitéesjusqu'à leur mort par des doses faibles de succinate
sodique d'hydrocortisone (3,3 mg/kg/jour) et 21 souris ont recu des
fortes doses (10 mg/kg/jour). Quinze souris contrôles ont recu du
solute sale. Le traitement au long cours avec l'une ou l'autre des
doses a effectivement limité Ia maladie rénale et allonge Ia durée de
vie. Cinquante six pour cent des animaux recevant Ia dose faible
ont dCveloppC des cancers et 38% des souris de cc groupe sont
mortes d'une atteinte rénale. Les cancers ont déterminé Ia mort de
76% des souris recevant une dose élevée. Le traitement au long
cours a été associé a une predominance des sarcomes, qui sont
apparus chez les souris Des etudes antérieures de ce labora-
toire avaient démontré une augmentation de Ia durée de vie au
moyen du traitement par Ic cyclophosphamide des souris NZB/
NZW. Quatre vingt dix sept pour cent des souris traitées par Ic
cyclophosphamide développent des nCoplasies, surtout des lym-
phomes ou des carcinomes. 11 est conclu que les néoplasies sur-
viennent chez les souris NZB/NZW âgées dont Ia vie a été prolon-
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gee par les drogues immunosuppressives ou antiinflammatoires.
Le traitement spécifique employd dans chacune des etudes a
cependant influence Ic type de néoplasie.
Hybrid New Zealand Black/New Zealand White
(NZB/NZW) mice spontaneously develop heteroge-
neous antinuclear antibodies (ANA) detected by in-
direct immunofluorescence [1], specific antibodies to
DNA (anti-DNA) [2], hypocomplementemia [3], and
immune complex nephritis [4]. Disease is acceler-
ated in females, and 50% offemale NZB/NZW mice
die with renal failure at 10 months of age [5]. These
animals are accepted as models of systemic lupus
erythematosus (SLE) [1]. Since single-drug therapy
with prednisone is used to treat most patients with
SLE, it is clearly important to determine if cortico-
steroid therapy prevents autoimmune disease in New
Zealand mice. Furthermore, the risk of oncogenesis
is increased when an immunologically abnormal host
is treated with immunosuppressive drugs [6, 7].The
incidence of neoplasms in NZB/NZW mice receiving
long-term corticosteroid treatment has not been de-
termined previously. This study was undertaken to
evaluate the effectiveness of prolonged hydrocorti-
sone therapy in preventing early death from renal
disease in NZB/NZW mice. Unlike other experi-
ments in which New Zealand mice were treated with
corticosteriod drugs, the experimental plan was de-
signed to assess both disease activity and oncogensis
in animals receiving hydrocortisone.
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Methods
Treatment protocol. Breeding and maintenancea
of New Zealand Black (NZB), New Zealand White
(NZW), and NZB/NZW mice in the Rackham Arthri-
tis Research Unit were described in another publica-
tion [7]. Hydrocortisone sodium succinate (Upjohn
Company, Kalamazoo, Mich.) was dissolved in ster-
ile 0.15 M sodium chloride immediately before use.
In the low-dose treatment group, 20 mice received
daily subcutaneous injections of hydrocortisone, 3.3
mg/kg of body wt in 0.1 ml of volume. The mean age
of these mice at the start of the study was 7 weeks
(±4 SEM). A separate high-dose treatment group of
21 mice received injections of hydrocortisone, 10 mg/
kg/day. The mean age of the high-dose treated mice
when therapy began was 8 weeks (± 0.4). Fifteen
control mice (mean age, 11 1 weeks) received daily
s.c. injections of 0.15 M sodium chloride solution, 0.1
ml. Because the supply of hybrid mice in our colony
was limited, treatment was not started simultane-
ously in each group of animals. Nevertheless, life-
spans overlapped in control and treated mice.
Mice were bled from the orbital plexus before
treatment was started and after 24 and 52 weeks of
treatment. Terminal blood samples were obtained
from 40 animals. Sera for ANA tests, anti-DNA
determinations, and complement assays were stored
in sealed capillary tubes at —20° C. Mice were exam-
ined daily, and animals were killed when they ap-
peared moribund or developed palpable masses.
Complete autopsy examinations were performed fol-
lowing a protocol described in an earlier publication
[7].
Histological studies. All tissue sections were ex-
amined for abnormalities which may have caused
death of the animal. Selected tumor tissue was
stained for collagen (van Gieson method) and for
myofibrils (Mallory phosphotungstic acid hematoxy-
un stain). Renal tissue from each animal was stained
with hematoxylin and eosin, and with Schiff sulfite
leukofuchsin (PAS). Severity of renal disease was
scored using an adaptation [8] of the method of
Pirani, Pollak, and Schwartz [91. Abnormalities were
counted in 20 glomeruli in a 4- cross-section of each
kidney. The glomerular lesions counted were: thick-
ening and hypercellularity of the mesangial stalk,
focal glomerular hypercellularity, thickening of the
glomerular basement membrane, diffuse glomerular
Animals used in these experiments were maintained in facilities
accredited by the American Association for Accreditation of Lab-
oratory Animal Care, and animal experiments were conducted
according to the protocol of the Institute of Laboratory Animal
Resources, NRC, NAS.
hypercellularity, fibrinoid degeneration, and crescent
formation. In our experience, periarterial collections
of lymphocytes in NZB/NZW mice coincide with
development of glomerulonephritis. Although the
pathological importance of these lymphocyte cuffs
has not been established, they are absent in mice
treated with the potent immunosuppressive drug cy-
clophosphamide [101. Mononuclear cell infiltrates
around renal arteries were graded on a scale of 0 to 4:
0—no lymphocytes, 1—few lymphocytes, 2—lympho-
cytes surrounded 25 to 50% of arterial wall, 3—lym-
phocytes surrounded 75% of arterial wall, 4—lympho-
cytes surrounded the entire artery.
Autoantihodies. Sera samples were tested for het-
erogeneous ANA on human leukocyte substrate with
an indirect immunofluorescent method [10]. Each
sample of mouse serum was tested undiluted and at
dilutions of 1:4, 1:16, 1:64, 1:256, and 1:1024. Values
were expressed as the highest tube number (1 — log2
of serum dilution) giving a positive test. DNA-bind-
ing in serum was determined using a modification of
the Farr technique [10]. This assay quantitated the
percent of 14C-double-stranded-DNA bound by 15 p.1
of heat-inactivated mouse serum. In this laboratory,
values greater than 20% are positive for anti-DNA.
Complement. Serum levels of the third component
of complement (C3) were determined by single radial
immunodiffusion. A pool of serum from healthy
Spb:(SW)BR mice (Spartan Research Animals, Inc.,
Haslett, Mich.) was assigned a value of 100 C3 U/2
p.1. Four dilutions of this reference serum were in-
cluded with unknown sera from control and treated
NZB/NZW mice on each immunodiffusion plate. Af-
ter incubation, diameters of precipitin rings formed
by the reference serum compared to individual dilu-
tions of the same serum plotted as a straight line on a
semi-log graph. Serum C3 levels were read from
these standard curves and expressed in arbitrary C3
units [11].
Statistical analysis. Chi-square analyses [12] and
calculations of Student's t test [12] were performed
using the MIDAS software package [13] within the
MTS system on the AMDAHL 470V/6 computer.
Results
Longevity. Ten mice died of iatrogenic causes.
These animals were excluded from studies of longev-
ity, incidence of neoplasia, and renal histology. Cu-
mulative deaths in all other control and treated mice
are illustrated in Figure 1. The first control mouse
died 15 weeks after the study began, and all mice in
the control group were dead after 72 weeks of obser-
vation. The mean age at death in control mice was 45
(sEM) 4 weeks. Both groups of hydrocortisone-
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Fig. 1. Cumulative deal/is in 46 control and hydrocortisone-
treated female NZB/NZW mice. Ten mice dying from iatrogenic
causes were excluded. Lifespans of mice receiving low-dose
(HSS. 3.3 mg/kg/day) or high-dose (HSS, 10 mg/kg/day) hydrocor-
tisone sodium succinate were prolonged significantly compared to
control mice.
treated animals had significantly increased lifespans.
The earliest death in a low-dose treated mouse oc-
curred after 18 weeks of treatment, and 14 of 16 mice
in this group were dead after 75 weeks of therapy. In
low-dose treated mice, the mean age at death was 57
7 weeks (compared to control mice, P = 0.03).
The oldest survivors in the study received low-dose
hydrocortisone (Fig. 1). One of these aged mice
developed malignant lymphoma at 121 weeks of age.
The other mouse died with widespread arteritis and
severe renal disease at the age of 123 weeks. In mice
treated with the high dose of hydrocortisone, longev-
ity was similar to "normal" strains of mice without
autoimmune disease. The first death occurred 52
weeks after the study began. Mean lifespan in high-
dose treated mice was 94 4 weeks; this value was
significantly greater than the mean age at death in
control mice (P < 0.00001). Two years after high-
dose treatment was started, three aged survivors
were killed to end the experiment.
Causes of death. Table I lists the causes of death
in control and hydrocortisone-treated mice. Control
mice: Thirteen saline-injected mice died with glomer-
• o ulonephritis and widespread arteritis, and two mice
• ° died when they were anesthetized for routine bleed-
ings. Low-dose treated mice: Nine animals died with
neoplasms, and six animals died with renal disease
and vasculitis. Pneumonia caused death in one
mouse, and four mice died of iatrogenic causes.
High-dose treated mice: Neoplasms were the most
common cause of death in mice receiving prolonged
therapy with high-dose hydrocortisone; 13 mice in
this group died with tumors. In contrast to mice
receiving low-dose therapy, only one animal in the
high-dose treatment group died with severe glomeru-
lonephritis. Another mouse receiving high-dose ther-
apy was killed when an epigastric mass appeared
after 84 weeks of treatment. On postmortem exami-
nation, the mouse had an enlarged liver with subcap-
sular necrosis and endothelial proliferation in hepatic
sinusoids. This change was attributed to drug toxic-
ity. One high-dose treated mouse died with purulent
endometritis; another mouse hemorrhaged from di-
lated ovarian vessels. Four mice in this group died
iatrogenic deaths.
Neoplasms. Twenty-four tumors arose in 22
treated mice, and two high-dose treated mice carried
two neoplasms apiece. In Table 2, neoplastic lesions
are separated into four categories on the basis of
morphology and staining characteristics. Sarcomas,
the most common malignancies, were found in 11 of
22 tumor-bearing mice. An unusual feature of these
sarcomas was their tendency to involve the repro-
ductive tract. The sarcomas identified in both groups
of hydrocortisone-treated mice were mesenchymal
sarcoma of uterus (4), granulosa-theca cell tumor of
ovary (4), leiomyosarcoma of ovary (1), liposarcoma
(1), and osteosarcoma (1). Lymphoreticular malig-
nancies were found in 6 of 22 mice with tumors. Four
mice had lymphoblastic lymphomas; two mice had
disseminated lymphomas of the follicular center
Table 1. Causes of death in control and hydrocortisone-treated NZB/NZW mice
Renal
Neoplasms
disease/
vasculitis
Drug
toxicity Infection Hemorrhage latrogenica Total
Controls 0 13 0 0 0 2 15
Low-dose hydrocortisone" 9 6 0 1 0 4 20
High-dose hydrocortisonee 13 1 1 1 1 4 21
a Five mice (2 controls, 2 low-dose-treated, I high-dose-treated) died when they were anesthetized for orbital bleeding. Two mice in the
low-dose treatment group were arbitrarily chosen to be killed for use in an electron microscope study in the 38th week of treatment. Three
aged mice in the high-dose treatment group were killed to end the experiment. Longevity data and postmortem findings in these animals were
excluded from this report.
b Therapeutic regime was hydrocortisone sodium succinate, 3.3 mg/kg/day s.c.
Therapeutic regime was hydrocortisone sodium succinate, 10 mg/kg/day s.c.
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Table 2. Neoplasms in NZB/NZW mice treated with low-dose or high-dose hydrocortisone
Sarcomas Lymphomas Carcinomas Others Total
Low-dose hydrocortisone 3 2 1 38 9
High-dose hydrocortisone 8 4 1 2" 15
a Benign teratoma of ovary (1), pulmonary adenoma (1), papilloma (I).
I) Granular cell myoblastoma (1), mixed type alveolar cell tumor of lung (I).
type, previously classified as reticulum cell tumor
type B of Dunn [14] but now thought to be of B cell
origin [15].
Renal abnormalities. Glomerular lesions in control
and treated mice are listed in Table 3. The mean
glomerular lesion count in kidneys from control mice
was 53 2, reflecting severe proliferative glomeruli-
tis. Characteristic glomerular lesions in a control
mouse are shown in Figure 2. Large grade 4 periar-
terial infiltrates were common, and fibnnoid necrosis
of renal arteries was found in 9 of 13 control mice. In
hydrocortisone-treated mice, the protective effect of
corticosteroid therapy was reflected in decreased
number of glomerular lesions (Figs. 3 and 4) and
suppressed arterial disease. The mean glomerular
lesion count in low-dose treated mice was 23 4,
periartenal lymphocytes were suppressed, and only
two of 16 mice had renal vasculitis. In the high-dose
treatment groups, the mean glomerular lesion score
was 23 2. Periarterial lymphocytes were minimal,
and 2 of 17 kidneys had arteritis. Glomerular lesions
were decreased significantly in low-dose treated
mice (P<O.OO1) and in high-dose treated mice
(P<O.OOl) compared to control mice.
Autoantibodies. Treatment with hydrocortisone
did not prevent the expected age-dependent appear-
ance of ANA in NZB/NZW mice. Before treatment
was started, ANA tests were positive in 33% of
control mice, in 14% of low-dose treated mice, and in
24% of high-dose treated mice. After 24 weeks, all
control mice were ANA-positive. ANA were present
in 13 of 14 low-dose animals and in 17 of2l high-dose
animals. One year after the study began, sera sam-
Table 3. Renal lesions in control and hydrocortisone-treated NZB/
NZW mice
pies from all control and treated mice contained
ANA. Positive tests reverted to negative in three
mice that received prolonged therapy with hydrocor-
tisone. Two of these mice developed lymphoreticular
malignancies, and the third mouse died with an ovar-
ian granulosa-theca cell neoplasm.
Titered ANA values are listed in Table 4. In the
first 24 weeks of the study, median ANA titers in
control mice increased from 0 to 7. Low-dose hydro-
cortisone treatment was not associated with de-
pressed ANA titers. Therapy with high-dose hydro-
cortisone transiently suppressed the expected age-
dependent increase of ANA titers. After 24 weeks of
treatment, mice in the high-dose group had a median
titer of 3. When these mice were evaluated after 52
weeks of treatment and at death, high ANA titers
reflected a vigorous autoantibody response.
Mean anti-DNA values in control mice increased
from 16% to 38% in the first 24 weeks of the study
Glomerular Penarterial
lesionsa lymphocytesb Arteritise
Controls 53±2 4(Oto4) 9/13
Low-dose hydrocortisone 23 4" 2(0 to 4) 2116
High-dose hycrocortisone 23 2d 2(Oto4) 2/17
a Mean number of lesions counted in 20 glomeruli SEM.
Median (range). Collections of lymphocytes around renal ar-
teiies were graded on a scale of 0 to 4.
Number of kidneys with arteritis/number of kidneys examined.
"Compared to control mice, P <0.001.
Fig. 2. A severly damaged glomerulusfro,n a 77-week-old control
female NZB/NZW mouse dying with renal disease, This shows
fib,inoid necrosis and crescent formation. (Mouse #689; hematox-
ylin and eosin stain; magnification, x420.)
Neoplasms in NZB/NZW mice 155
Fig. 3. After 70 weeks of therapy with low-dose hydrocortisone
sodium succinate (3.3 mg/kg/day). This 77-week-old mouse died
with diffuse vasculitis and sarcoma of the uterus. Renal glomerular
histology did not show inflammatory changes. Thick basement
membrane and an area of cellular proliferation are present in this
glomerulus. This mouse died at the same age as the untreated
control mouse whose renal histology is shown in Figure 1. (mouse
#536, hematoxylin and eosin, x420.)
Table 4. Autoantibody levels in control and hydrocortisone-treated
NZB/NZW mice
Weeks of treatment
Terminal0 24 52
Titered ANA
Controls 0(0 to 5)
[151
7 (3 to 9)
[12]
9
[1]
5 (Ito 9)
[121
Low-dose
hydrocortisone 0(0 to 3)
[141
7 (0 to 9)
[181
7(5 to 9)
[101
5(0 to 11)
[111
High-dose
hydrocortisone 0(0 to 5)
[211
3(0 to 7)
[21]
7(1 to 11)
[20]
5(0 to 9)
[171
Anti-DNA
Controls 16 06b 38 5 45 21 I
Low-dose
hydrocortisone 14 0.3 37 3 26 4C 22 3
High-dose
hydrocortisone 14 03 31 3 41 3 17 t
a Median (range). Values are expressed as the highest tube num-
ber (I—log2 of serum dilution) giving a positive test for heteroge-
neous ANA with an indirect immunofluorescent technique. Brack-
ets enclose the number of mice tested at each bleeding.
b Mean SEM. A modification of the Farr technique was used to
test sera for specific antibodies to double-stranded DNA. Values
are expressed as percent of '4C-DNA bound to 0.015 ml of mouse
serum.
Compared to high-dose treated mice, P = 0.01.
Fig. 4. A 100-week-old mouse thai died with widespread lympho-
blastic lymphoma and alveolar cell tumor of the lung after 91
weeks of high-dose hydrocortisone therapy (10 mg/kg/day). Gb-
merular abnormalities in renal tissue from this mouse were charac-
teristic of the changes in aged mice receiving high-dose treatment.
Focal hypercellularity and thick basement membrane were present
in most renal gbomeruli. (Mouse #804, hematoxylin and eosin,
>< 490.)
(Table 4). Anti-DNA levels in hydrocortisone-
treated mice were similar to controls. After one year
of therapy, mean anti-DNA in the low-dose group
was 26%. This value was significantly smaller than
the corresponding value (4 1%) in high-dose treated
mice (P=O.Ol). Mean anti-DNA levels were low in
terminal sera from all three groups of mice.
Complement (Table 5). C3 levels were measured in
sera samples collected from a limited number of
animals before treatment and death. Based upon the
work of others, it was anticipated that progressive
immune complex disease in New Zealand mice
would be associated with progressively falling C3
levels [31. In control and treated mice, pretreatment
C3 values were higher than C3 values in terminal
sera. C3 levels did not change significantly, however,
in any group of mice during the course of this study.
Discussion
Disease in NZB!NZW mice is analogous to SLE in
humans, and many investigators have used these
animals to test the therapeutic efficacy of immuno-
suppressive and antiinflammatory drugs. Early stud-
ies showed that corticosteroids suppressed autoim-
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Table 5. C3 levels in control and hydrocortisone-treated micea
Before
treatment Terminal
Controls 120 7
[13]
104
[71
17
Low-dose
hydrocortisone 130 27
[51
102
[11]
14
High-dose
hydrocortisone 119 9
[18]
90
[16]
13
U Mean SEM. Brackets enclose the number of mice tested.
Serum C, levels were determined by radial immunodiffusion. Val-
ues were expressed as arbitrary C, units, determined by compar-
ing precipitin ring diameters produced by NZB/NZW serum with
diameters produced by twofold dilutions of standard pooled
mouse serum.
mune renal disease in New Zealand mice. In 1968,
Casey reported that glomerulonephritis was sup-
pressed in NZB/NZW mice receiving betametha-
sone, 30 gIday, for 13 to 14 weeks [16]. Subse-
quently, Hahn, Bagby, and Hamilton treated female
NZB/NZW mice with prednisolone, 5 mg/kg/day
(given 6 days/week), from 10 weeks of age until
death. Mean lifespan in treated mice was 44 weeks,
compared to 35 weeks in control mice [171. In an-
other study, female NZB/NZW mice received daily
doses of methyiprednisolone, 1.5, 4.5, or 10 mg/kg,
for 2 or 3 months, and the animals were observed for
longevity. Lifespans were lengthened appreciably in
mice treated with the highest dose of methyipredni-
solone [18, 191.
In the current study, tifespans were prolonged
significantly in both groups of mice treated with
hydrocortisone. The mean lifespan in high-dose
treated mice was 94 weeks, and seven mice in this
group lived longer than 2 yr. To our knowledge, this
is the greatest longevity reported in any group of
treated female NZB/NZW mice. In other laborato-
ries, the superior therapeutic effectiveness of corti-
costeroid drugs may have been masked by prema-
ture deaths from drug toxicity or respiratory
infections. In one experiment, severe hepatotoxicity
developed in 15 of 37 NZB/NZW mice treated with
prednisolone, 5 mg/kg/day [171. Only one treated
mouse in the current study died with liver disease.
Longevity studies employing prednisolone-treated
NZB/NZW mice have included treated and control
animals who died with bronchopneumonia [20]. For-
tunately, infections were a minor problem in hydro-
cortisone-treated mice in this study. Only 2 of 41
treated animals had postmortem evidence of in-
fection.
Antibodies to double-stranded DNA participate
directly in the pathogenesis of immune complex ne-
phritis in New Zealand mice [4]. In untreated ani-
mals, increased serum anti-DNA is a marker of ac
tive autoimmune disease which precedes renal
insufficiency. Nevertheless, hydrocortisone-treated
mice with increased longevity produced anti-DNA
throughout the first 24 weeks of treatment. The de-
layed onset of renal insufficiency in these animals
may be attributed to the potent antiinflammatory
action of hydrocortisone [21]. This impression was
reinforced by the histological appearance of kidney
tissue from mice in the low-dose and high-dose treat-
ment groups. Thick basement membranes and seg-
mental hypercellularity were common, but exudative
changes were not observed in glomeruli from hydro-
cortisone-treated mice.
In this laboratory, lifelong therapy with immuno-
suppressive doses of cyclophosphamide has been
associated with significant prolongation of life in two
separate groups of female NZB/NZW mice. In an
earlier study, neoplasms developed in nine of 10
mice receiving s.c. injections of cyclophosphamide,
8 mg/kg/day [7]. Recently, 15 female NZB/NZW
mice were treated with cyclophosphamide, 5.7 mgI
kg/day. These animals were littermates of the low-
dose treatment mice described in this report, and
detailed results of their therapy will be reported else-
where. All 15 mice developed neoplasms, and 11
mice carried multiple neoplasms. Twenty-seven tu-
mors arose in this treatment group; eight carcino-
mas, seven pulmonary adenomas, six lymphomas,
four sarcomas, one histiocytoma, and one chon-
droma. Although a high incidence of neoplasms was
a consistent finding in NZB/NZW mice treated with
cyclophosphamide or hydrocortisone, patterns of
neoplasia differed in the various treatment groups. In
cyclophosphamide-treated mice, lymphomas, pul-
monary adenomas, and carcinomas were common
neoplasms. In hydrocortisone-treated mice, 53% of
tumors were sarcomas.
NZB/NZW mice have two characteristics which
should predispose them to develop tumors. These
animals carry oncogenic C-type viruses [22], and
they lose protective T-cell function after S months of
age [23, 24]. Nevertheless, unmanipulated New Zea-
land mice in our colony have a low background
incidence of neoplasia. Detailed autopsy examina-
tions revealed malignancies in 3 of 46 untreated
NZBINZW mice who were observed throughout
their lifespans [7] (WALKER: to be published). Al-
though premature death from autoimmune disease
may have explained small numbers of neoplasms in
female mice, our young animals were not tumor-
prone. In mice treated with hydrocortisone or cyclo-
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phosphamide, neoplasms were the major cause of
death. Most tumors appeared in aged mice after a
prolonged course of therapy. It is important to note
that neoplasms are a common cause of death in old
mice from stocks which do not develop autoimmune
disease [25]. The current study did not separate the
effects of aging from possible oncogenic effects of
prolonged therapy of autoimmune disease. Never-
theless, the results of these therapeutic studies sup-
port the conclusion that neoplasia is an important
consequence of long-term treatment of autoimmune
disease in hybrid New Zealand mice.
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